As Part of Affy, Neomorphic s Drug Dream Still Alive | GenomeWeb

NEW YORK, Oct 2 - First it dropped the word software from its name as it reinvented itself into a computationally-driven drug-discovery company. Now the name Neomorphic is destined for the dustbin of corporate history as it is swallowed up by chipmaker Affymetrix (Nasdaq: AFFX).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.